<DOC>
	<DOCNO>NCT02380365</DOCNO>
	<brief_summary>Experimental intervention : electrocardiography . Control intervention : none Duration intervention per patient/subject : 5 min , observation 6 month Key inclusion criterion : - outpatient lung transplantation ( single , double combine ) - outpatient wait list lung transplantation Key exclusion criterion : • inform consent</brief_summary>
	<brief_title>QT-Prolongation Lung Transplantation</brief_title>
	<detailed_description>Primary endpoint : • prevalence significant QTc-interval prolongation ( 500 msec ) lung transplantation Key secondary endpoint ( ) : - prevalence QTc-interval prolongation ( &gt; 440 msec ) lung transplantation - prevalence PQ prolongation ( 200 msec sec ) lung transplantation - prevalence QRS prolongation ( 120 msec ) lung transplantation - prevalence QTc-prolonging drug drug regimen lung transplantation - influence long-term neo-macrolide ( e.g . azithromycin ) QTc interval lung transplantation - intra-individual difference QTc interval lung transplantation - incidence QTc-interval prolongation ( &gt; 440 msec ) lung transplantation - incidence QTc-interval prolongation ( &gt; 440 msec increase 50msec ) initiation new QTc prolonging drug ( especially neo-macrolides ) - reversal QTc-interval prolongation ( 440 msec low decrease 50msec ) stop QTc prolong drug - Assessment safety : - Incidence new onset heart rhythm disorder 6 month follow-up</detailed_description>
	<mesh_term>Long QT Syndrome</mesh_term>
	<criteria>outpatient lung transplantation ( single , double combine ) outpatient wait list lung transplantation inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>lung transplantation</keyword>
	<keyword>electrocardiography</keyword>
	<keyword>macrolides</keyword>
	<keyword>QTc interval</keyword>
	<keyword>arrhythmia</keyword>
</DOC>